A new analysis of the SELECT trial published in JAMA Cardiology found that semaglutide 2.4 mg (Wegovy) delivered cardiovascular benefits versus placebo consistently across all frailty levels. The most frail patients experienced the greatest quality-of-life improvements. The findings address concerns that GLP-1 therapies may be less safe or effective in frail populations.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.